Collaborative Agreements (Details 2) (Novartis, USD $)	3 Months Ended	36 Months Ended	0 Months Ended	1 Months Ended		3 Months Ended	36 Months Ended											0 Months Ended	3 Months Ended		36 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Mar. 29, 2013 Right-to-test agreement item	Oct. 31, 2010 Right-to-test agreement item	Oct. 31, 2013 Right-to-test agreement Subsequent event	Sep. 30, 2013 Development and Commercialization License	Sep. 30, 2013 Development and Commercialization License	Mar. 29, 2013 Development and Commercialization License	Oct. 31, 2010 Development and Commercialization License	Oct. 31, 2010 Development and Commercialization License Maximum	Sep. 30, 2013 Development and Commercialization License Development milestones	Mar. 29, 2013 Development and Commercialization License Development milestones	Oct. 31, 2010 Development and Commercialization License Development milestones	Mar. 29, 2013 Development and Commercialization License Regulatory milestones	Oct. 31, 2010 Development and Commercialization License Regulatory milestones	Mar. 29, 2013 Development and Commercialization License Sales milestones	Oct. 31, 2010 Development and Commercialization License Sales milestones	Mar. 29, 2013 Exclusive development and commercialization license item	Sep. 30, 2013 Exclusive development and commercialization license item	Mar. 29, 2013 Non-exclusive development and commercialization license Minimum	Sep. 30, 2013 Future Technological Improvements	Sep. 30, 2013 Research Services
Collaborative Agreements disclosures
Term of agreement				3 years	3 years
Number of extension terms				1
Term of extension of agreement				1 year	1 year
Payments for extension of agreement					$ 5,000,000
Payments received under collaboration agreement		55,200,000	1,000,000	45,000,000	1,000,000		55,400,000														4,100,000	710,000
License exercise fee, per license									1,000,000
Potential milestone payment receivable								199,500,000		199,500,000	5,000,000	22,500,000	22,500,000	77,000,000	77,000,000	100,000,000	100,000,000
Number of development and commercialization licenses taken																		1	1
Number of pre-defined and related undisclosed targets			2
Agreed upon fee receivable on conversion of non-exclusive target to an exclusive target																				5,000,000
Payments received under collaboration agreement in connection with amended agreement			3,500,000
Potential milestone payments under second option								$ 238,000,000				$ 22,500,000		$ 115,500,000		$ 100,000,000
Allocation of fees to deliverables
Estimated utilization period after commercialization	10 years
Discount rate (as a percent)	16.00%
Estimated term of development and commercialization license						25 years